The MANTA 1-year results: The anti-VEGF debate continues

British Journal of Ophthalmology

Volumn 97, Issue 3, 2013, Pages 248-250

  Ehlers, Justis P ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; RANIBIZUMAB;

ARTERY THROMBOSIS; CLINICAL EFFECTIVENESS; CLINICAL PROTOCOL; COMPARATIVE EFFECTIVENESS; DRUG APPROVAL; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EDITORIAL; ENDOPHTHALMITIS; EVIDENCE BASED MEDICINE; HEART FAILURE; HUMAN; MEDICAL DECISION MAKING; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETINA MACULA AGE RELATED DEGENERATION; RETREATMENT; VISUAL ACUITY;

ANTIBODIES, MONOCLONAL, HUMANIZED; FEMALE; HUMANS; MACULAR DEGENERATION; MALE; RETINAL NEOVASCULARIZATION; VISUAL ACUITY;

EID: 84874662954     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjophthalmol-2012-302489     Document Type: Editorial

References (18)

1. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355:1432-44.
2. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355: 1419-31.
3. Browning DJ, Kaiser PK, Rosenfeld PJ, et al. Aflibercept for age-related macular degeneration: a game-changer or quiet addition? Am J Ophthalmol 2012;154:222-6.
4. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42.
5. Curtis LH, Hammill BG, Schulman KA, et al. Risks of mortality, myocardial infarction, bleeding, and stroke associated with therapies for age-related macular degeneration. Arch Ophthalmol 2010;128:1273-9.
6. Goldberg RA, Flynn HW Jr., Isom RF, et al. An outbreak of streptococcus endophthalmitis after intravitreal injection of bevacizumab. Am J Ophthalmol 2012;153:204-8 e1.
7. Gonzalez S, Rosenfeld PJ, Stewart MW, et al. Avastin doesn't blind people, people blind people. Am J Ophthalmol 2012;153:196-203 e1.
8. Sun X, Xu X, Zhang X. Counterfeit bevacizumab and endophthalmitis. N Engl J Med 2011;365:378-9; author reply 9.
9. Martin DF, Maguire MG, Ying GS, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011;364:1897-908.
10. Stewart MW. Aflibercept (VEGF Trap-eye): the newest anti-VEGF drug. Br J Ophthalmol 2012;96: 1157-8.
11. Bowler GS, Fayers T, Gouws P. 5.7 Times more expensive than liquid gold. Br J Ophthalmol 2012;96:1046.
12. Krebs I, Schmetterer L, Boltz A, et al. A randomized observer and subject masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age-related macular degeneration. Br J Ophthalmol 2013;97:266-71.
13. Chakravarthy U, Harding SP, Rogers CA, et al. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology 2012;119:1399-411.
14. Martin DF, Maguire MG, Fine SL, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 2012;119:1388-98.
15. Engelbert M, Zweifel SA, Freund KB. Long-term follow-up for type 1 (subretinal pigment epithelium) neovascularization using a modified "treat and extend" dosing regimen of intravitreal antivascular endothelial growth factor therapy. Retina 2010;30:1368-75.
16. Spaide R. Ranibizumab according to need: a treatment for age-related macular degeneration. Am J Ophthalmol 2007;143:679-80.
17. Gupta OP, Shienbaum G, Patel AH, et al. A treat and extend regimen using ranibizumab for neovascular age-related macular degeneration clinical and economic impact. Ophthalmology 2010;117:2134-40.
18. Shienbaum G, Gupta OP, Fecarotta C, et al. Bevacizumab for neovascular age-related macular degeneration using a treat-and-extend regimen: clinical and economic impact. Am J Ophthalmol 2012;153:468-73 e1.